

Prof Jim McCaul (www.profmccaul.co.uk)

Consultant Surgeon and Professor Emeritus
Maxillofacial Unit, Queen Elizabeth University Hospital Glasgow, NHSGGC
and Institute for Cancer Therapeutics, University of Bradford

Among 13 National and International Awards to date he was awarded the British Association of Oral and Maxillofacial Surgeons (BAOMS) President's award for research optimising patient care in major surgery in 2012 and the BAOMS Surgery Prize in recognition of his contribution in the Head & Neck field. His team won the BAOMS Norman Rowe Clinical Research Prize in 2014. He moved to Queen Elizabeth University Hospital in Glasgow in 2017, one of the highest throughput head and neck cancer centres in the world, treating more than 700 head and neck cancers per annum



He was UK NCRI Lead for Head & Neck Cancer Surgery Research 2012 to 2020, Research Lead for BAOMS 2012 to 2020. He is Chief Investigator of the CRUK LIHNCS trial, which successfully recruited 419 patients to time and target, an international first for a mouth cancer surgical clinical trial. He is co-investigator in a further 8 clinical trials in the UK and collaborates internationally with colleagues in Europe and North America. These include analysis of new technologies for free flap monitoring and new pharmacologic treatments for ORN

He is Assistant Editor of the International Journal of Surgery and the International Journal of Surgery Case Reports and reviews for 12 other international medical research journals. He is author of 5 book chapters and has presented and published 97 peer reviewed articles and more than 160 research abstracts at national and international meetings.

His clinical interests are in all pathology of the face, mouth, jaws, head and neck and salivary glands. His particular interests include diagnosis and surgical management of salivary gland cancer (he is one of four authors of the new draft of UK Salivary gland cancer management guidelines) and early detection of precancer tissue and defining the precise extent of cancer and pre-cancer in patients with oral cavity and oro-pharynx tumours in order to accurately remove and treat cancer whilst minimising impact on oral and facial function, appearance and senses.

“I have always believed that patients with salivary gland cancers have not been well served by the broader international medical research community. As a rare disorder patient group, comprising the most diverse range of cancers of any body-site or tissue, meaningful research to improve treatment requires to be national and international and closely collaborative. This patient group has not been subject to widespread, international, effective research initiatives even in recent times. I would like very much to be part of changing this.

Many of the most challenging and rewarding patients to treat have been those with rare salivary gland malignancies. I have been and remain extremely motivated to enhance treatment options and outcomes for this patient group.

Throughout these 18 years I have been an active researcher, both leading and running my own trials and those of others in the field and leading UK head and neck cancer research in a number of UK roles. These latter and my research credentials are detailed in the short biography I have submitted.”